(Q34569963)

3 August 2017

1 reference

title

Prediction of the response of colorectal cancer to systemic therapy (English)

1 reference

3 August 2017

1 reference

1 reference

2

Susan D Richman

1 reference

3 August 2017

Julian W Adlard

1

0 references

author name string

Matthew T Seymour

series ordinal

3

1 reference

PubMed ID

11902527

3 August 2017

Phil Quirke

series ordinal

4

1 reference

3 August 2017

1 February 2002

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

3

1 reference

3 August 2017

75-82

1 reference

3 August 2017

2

1 reference

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Irinotecan in the treatment of colorectal cancer: clinical overview

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Oxaliplatin: a new agent for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Lessons from hereditary colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

DNA microarrays in medical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

bcl-2 protein expression is associated with better prognosis in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Prognostic markers for colorectal cancer: expression of P53 and BCL2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

K-ras and p16 aberrations confer poor prognosis in human colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Inhibition of CDKs as a therapeutic modality.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900648-4

7 January 2021

10.1016/S1470-2045(02)00648-4

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11902527